HOUSTON (Sept. 2, 2015) OrthoAccel® Technologies, Inc. announces that orthodontic industry veteran Frank Grunau has joined the company as regional director for Europe, Middle East and Africa (EMEA). As the newly appointed EMEA regional director, Grunau will serve as a key member of the executive leadership team and will lead an aggressive EU growth strategy for AcceleDent®, an FDA-cleared, Class II medical device that speeds up orthodontic treatment by as much as 50 percent. AcceleDent is manufactured by OrthoAccel and is currently cleared for use in over 30 EU countries.
Grunau comes to OrthoAccel with extensive industry experience, including time with Align Technology, Inc., makers of Invisalign®, where he served in Europe as sales and sales operations director, and most recently as vice president of sales and marketing, EMEA with a strong focus in developing emerging markets. Additionally, his 26 years of medical device and technology sales experience span brands from leading global companies including Zimmer Spine, Boston Scientific, and Bausch and Lomb.
Throughout his career, Grunau’s strategic approach to business development and in-depth market experience has led to major business expansions, penetration of new territories, and rapid growth of product sales, including his years at Align Technology, where he grew revenues in Europe by more than 33% CAGR (compound annual growth rate) over a six-year period.
“We’re very excited to announce Frank Grunau as OrthoAccel’s new regional director for EMEA,” said Michael K. Lowe, president and CEO of OrthoAccel. “The EU is an important part of AcceleDent’s continued growth strategy as it represents the second largest orthodontic market in the world. I’m confident that Frank’s strong medical device background and extensive experience in orthodontics will result in rapid expansion in the EU, paralleling the rapid expansion we are experiencing in the U.S.”
Lowe adds that Grunau joins OrthoAccel at a pivotal time in the innovative company’s history as the organization focuses on expanding its brand dominance as the industry leader in accelerated orthodontics. Grunau commented, “This is an exciting time and I am very proud to be part of this great organization, leading the growth strategy for AcceleDent in EMEA.”
Along with Lowe and Grunau, OrthoAccel’s executive leadership team includes Kelly Enos, chief financial officer and vice president of finance and administration; Kathleen Malaspina, chief innovation officer and vice president of marketing; Doug Bukaty, vice president of sales; and Jeff Layton, chief operations officer. In the EU market, Michael Wenderoth, who currently serves as an EU advisor and consultant to OrthoAccel, will continue in that role.
For more information about OrthoAccel Technologies, Inc. and AcceleDent visit acceledent.com.
About OrthoAccel® Technologies, Inc.
Based in Houston, Texas, OrthoAccel® Technologies, Inc. is a privately owned medical device company engaged in the development, manufacturing and marketing of products to enhance dental care and orthodontic treatment. OrthoAccel developed and sells AcceleDent® Aura, the first FDA-cleared clinical approach to safely accelerate orthodontic tooth movement by applying gentle micropulses via SoftPulse Technology® as a complement to existing orthodontic treatment. More information can be found at acceledent.com and acceledent.co.uk or requested via firstname.lastname@example.org.